Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. has announced breakthrough research showing that 86% of surgical site infections are linked to the patient’s own microbiome, with 59% resistant to antibiotics used during surgery. Their light-activated antimicrobial, Steriwave®, offers a promising alternative to traditional antibiotics, effectively preventing infections without contributing to antimicrobial resistance. This innovative treatment aligns with global guidelines recommending nasal decolonization to reduce surgical site infections, which are a significant concern in healthcare.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
